LeBel Carl
Chief Development Officer at KRRO; Chief Scientific Officer at Otonomy, Inc.
- Sold, on record
- $1.7M
- Dollars the filings state
- Form 4 sales
- 8
- Latest Jul 6, 2022
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- KRROKorro Bio, Inc.Chief Development Officer
- Otonomy, Inc.Chief Scientific Officer
Sales by reason
Form 4 sales per year, every sale on record.
Sales by company
- Otonomy, Inc.74,375 shares
- KRRO9,040 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Otonomy, Inc.UnusualSep 21, 2015 2015
Sold 21,250 shares at $24.36 ($518k)
LeBel Carl, Chief Scientific Officer
Sold 70.4% of holdings ($735k position)8,920 shares leftFirst sale on recordFiling
- 2 Form 4 sale Otonomy, Inc.UnusualDec 21, 2015 +91 days
Sold 21,250 shares at $28.04 ($596k)
LeBel Carl, Chief Scientific Officer
Sold 70.4% of holdings ($846k position)8,920 shares leftFiling
- 3 Form 4 sale Otonomy, Inc.UnusualSep 6, 2016 +260 days
Sold 21,250 shares at $17.95 ($381k)
LeBel Carl, Chief Scientific Officer
Sold 69.2% of holdings ($551k position)9,458 shares leftFiling
- 4 Form 4 sale Otonomy, Inc.UnusualNov 21, 2016 +76 days
Sold 10,625 shares at $18.07 ($192k)
LeBel Carl, Chief Scientific Officer
Sold 52.9% of holdings ($363k position)9,458 shares left0.5x usual sizeFiling
- 5 Form 4 sale KRROPlan not statedFeb 15, 2022 +1912 days
Sold 844 shares at $4.33 ($4k)
LeBel Carl, Chief Development Officer
Sold 5.4% of holdings ($68k position)14,901 shares leftFirst sale on recordFiling
- 6 Form 4 sale KRROPlan not statedFeb 17, 2022 +2 days
Sold 1,732 shares at $4.31 ($7k)
LeBel Carl, Chief Development Officer
Sold 11.6% of holdings ($64k position)13,169 shares leftFiling
- 7 Form 4 sale KRROPlan not statedFeb 22, 2022 +5 days
Sold 2,043 shares at $3.69 ($8k)
LeBel Carl, Chief Development Officer
Sold 15.5% of holdings ($49k position)11,126 shares leftFiling
- 8 Form 4 sale KRROPlan not statedJul 6, 2022 +134 days
Sold 4,421 shares at $1.52 ($7k)
LeBel Carl, Chief Development Officer
Sold 14.4% of holdings ($47k position)26,343 shares left2.6x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (8)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2022 | Jul 7, 2022 | KRRO | Chief Development Officer | Form 4 sale | 4,421 | $7k | 14.4% | Plan not stated | SEC |
| Feb 22, 2022 | Feb 23, 2022 | KRRO | Chief Development Officer | Form 4 sale | 2,043 | $8k | 15.5% | Plan not stated | SEC |
| Feb 17, 2022 | Feb 18, 2022 | KRRO | Chief Development Officer | Form 4 sale | 1,732 | $7k | 11.6% | Plan not stated | SEC |
| Feb 15, 2022 | Feb 16, 2022 | KRRO | Chief Development Officer | Form 4 sale | 844 | $4k | 5.4% | Plan not stated | SEC |
| Nov 21, 2016 | Nov 22, 2016 | Otonomy, Inc. | Chief Scientific Officer | Form 4 sale | 10,625 | $192k | 52.9% | Unusual | SEC |
| Sep 6, 2016 | Sep 8, 2016 | Otonomy, Inc. | Chief Scientific Officer | Form 4 sale | 21,250 | $381k | 69.2% | Unusual | SEC |
| Dec 21, 2015 | Dec 22, 2015 | Otonomy, Inc. | Chief Scientific Officer | Form 4 sale | 21,250 | $596k | 70.4% | Unusual | SEC |
| Sep 21, 2015 | Sep 22, 2015 | Otonomy, Inc. | Chief Scientific Officer | Form 4 sale | 21,250 | $518k | 70.4% | Unusual | SEC |